Meeting
2018 ASCO Annual Meeting
A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
Authors
Sophie Papa
Guy's And St Thomas NHS Foundation Trust, London, United Kingdom
Sophie Papa , Antonella Adami , Michael Metoudi , Daniela Achkova , May van Schalkwyk , Ana Parente Pereira , Leticia Bosshard-Carter , Lynsey Whilding , Sjoukie van der Stegen , David Davies , Farzin Farzaneh , Teresa Guerrero Urbano , Jean-Pierre Jeannon , James F. Spicer , John Maher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT01818323
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3046)
DOI
10.1200/JCO.2018.36.15_suppl.3046
Abstract #
3046
Poster Bd #
260
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Adoptive immunotherapy of acute myeloid leukemia (AML) with allogenic CAR t-cells targeting CD123.
First Author: Roman Galetto
Poster
2023 ASCO Annual Meeting
Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
First Author: Mason Webb
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2023 ASCO Annual Meeting
ENLIGHten-01: A phase 1 study of fluorescein-specific (FITC-E2)-CAR T cells in combination with folate-fluorescein (UB-TT170) for osteosarcoma.
First Author: Catherine Michelle Albert